NKTR-214 short attack - Mr. Liu | DVAX Message Board Posts

Dynavax Technologies Corporation

  DVAX website

DVAX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1400 of 1641  at  11/12/2018 8:40:52 PM  by

liuyiiv

The following message was updated on 11/12/2018 8:44:36 PM.

 In response to msg 1399 by  fairvalueforyou
view thread

Re: NKTR-214 short attack - Mr. Liu

  
  Thanks for inviting.
 
If you look at ESMO poster, SD-101 also has 70-72% 0 prior line of therapy (treatment naive) patients in both 2mg and 8mg group. So no big difference.
 
Scientifically, it is possible, with PD-1 monotherapy, some PR didn't turn into CR due to exhaustion of T cells. NKTR-214 may prevent that by boosting T cells with IL-2.
 
On the other hand, SD-101 can turn non responder to responder by activating DCs. Nonetheless, I expect SD-101 CR eventually reach 24-27% as many patients only had 1-2 scans but CR come at 2,3,4,5th scans.
 
At the end of the day, it may be the best to combine all three. We may reach 90% ORR and 50% CR.
 
With that said, I only own DVAX, no NKTR.
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 5     Views: 189
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
1401 Re: NKTR-214 short attack - Mr. Liu fairvalueforyou 1 11/12/2018 10:05:15 PM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...